Office of Commercialization and Economic Development
Office of Technology Commercialization

Small Molecules for the Treatment of Central Nervous System Disorders

Technology #10-0118

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Jian Jin
Managed By
Champ Gupton
Commercialization Manager 919.966.4132
Patent Protection
US Patent US 9156822

Small molecules that can bind dopamine receptor D2 have been developed for the treatment of central nervous system (CNS) disorders. The compounds developed have both agonist and antagonist activity and were proven effective in in vitro and in vivo models. Significantly, in hyperlocomotion mouse models, these compounds showed efficacy and potency without inducing catalepsy. These compounds can be used to treat CNS disorders such as depressions, schizophrenia, and Tourrette’s syndrome

Related Publications: